Amicus Therapeutics, a publicly traded biopharmaceutical firm focused on rare diseases, has moved nearly 100 R&D professionals over the past year into 3675 Market St., in Philadelphia’s University City, and plans to add another 100.
“Here in Philadelphia is where we are going to do all our science,” says John Crowley, chief executive of Amicus, which is based in Cranbury Township, near Princeton and calls its new West Philly labs the Global Research & Gene Therapy Center of Excellence.
Crowley also calls Philadelphia “the Cradle of Cures,” a label that might possibly stick better than “Cellicon Valley” and the other titles that the city’s bio boosters have pushed in recent years.